GB201910125D0 - Treatments of angioedema - Google Patents

Treatments of angioedema

Info

Publication number
GB201910125D0
GB201910125D0 GBGB1910125.2A GB201910125A GB201910125D0 GB 201910125 D0 GB201910125 D0 GB 201910125D0 GB 201910125 A GB201910125 A GB 201910125A GB 201910125 D0 GB201910125 D0 GB 201910125D0
Authority
GB
United Kingdom
Prior art keywords
angioedema
treatments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1910125.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kalvista Pharmaceuticals Ltd
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Priority to GBGB1910125.2A priority Critical patent/GB201910125D0/en
Publication of GB201910125D0 publication Critical patent/GB201910125D0/en
Priority to CA3142220A priority patent/CA3142220A1/en
Priority to EP20734285.8A priority patent/EP3982961A1/en
Priority to PH1/2021/552967A priority patent/PH12021552967A1/en
Priority to TW109120109A priority patent/TW202112371A/zh
Priority to JP2021571935A priority patent/JP7640474B2/ja
Priority to US17/617,456 priority patent/US20220226293A1/en
Priority to AU2020293616A priority patent/AU2020293616A1/en
Priority to SG11202113375PA priority patent/SG11202113375PA/en
Priority to PCT/GB2020/051441 priority patent/WO2020249979A1/en
Priority to MA056188A priority patent/MA56188A/fr
Priority to MX2021014558A priority patent/MX2021014558A/es
Priority to CN202080043658.4A priority patent/CN113993520A/zh
Priority to BR112021024447A priority patent/BR112021024447A2/pt
Priority to KR1020217043375A priority patent/KR20220024221A/ko
Priority to CN202410143627.6A priority patent/CN118078821A/zh
Priority to ARP200101682A priority patent/AR119159A1/es
Priority to IL288612A priority patent/IL288612A/en
Priority to CL2021003243A priority patent/CL2021003243A1/es
Priority to CL2023000699A priority patent/CL2023000699A1/es
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
GBGB1910125.2A 2019-06-14 2019-07-15 Treatments of angioedema Ceased GB201910125D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GBGB1910125.2A GB201910125D0 (en) 2019-07-15 2019-07-15 Treatments of angioedema
CN202410143627.6A CN118078821A (zh) 2019-06-14 2020-06-15 血管性水肿的治疗
SG11202113375PA SG11202113375PA (en) 2019-06-14 2020-06-15 Treatments of angioedema
MA056188A MA56188A (fr) 2019-06-14 2020-06-15 Traitements de l'oedème de quincke
PH1/2021/552967A PH12021552967A1 (en) 2019-06-14 2020-06-15 Treatments of angioedema
TW109120109A TW202112371A (zh) 2019-06-14 2020-06-15 血管性水腫之治療
JP2021571935A JP7640474B2 (ja) 2019-06-14 2020-06-15 血管性浮腫の治療
US17/617,456 US20220226293A1 (en) 2019-06-14 2020-06-15 Treatments of angioedema
AU2020293616A AU2020293616A1 (en) 2019-06-14 2020-06-15 Treatments of angioedema
CA3142220A CA3142220A1 (en) 2019-06-14 2020-06-15 Treatments of angioedema
PCT/GB2020/051441 WO2020249979A1 (en) 2019-06-14 2020-06-15 Treatments of angioedema
EP20734285.8A EP3982961A1 (en) 2019-06-14 2020-06-15 Treatments of angioedema
MX2021014558A MX2021014558A (es) 2019-06-14 2020-06-15 Tratamientos de angioedema.
CN202080043658.4A CN113993520A (zh) 2019-06-14 2020-06-15 血管性水肿的治疗
BR112021024447A BR112021024447A2 (pt) 2019-06-14 2020-06-15 Tratamentos de angioedema
KR1020217043375A KR20220024221A (ko) 2019-06-14 2020-06-15 혈관부종의 치료 방법
ARP200101682A AR119159A1 (es) 2019-06-14 2020-06-16 Tratamientos de angioedema
IL288612A IL288612A (en) 2019-06-14 2021-12-02 Treatments for angioedema
CL2021003243A CL2021003243A1 (es) 2019-06-14 2021-12-06 Tratamientos de angioedema
CL2023000699A CL2023000699A1 (es) 2019-06-14 2023-03-10 Tratamientos de angioedema

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1910125.2A GB201910125D0 (en) 2019-07-15 2019-07-15 Treatments of angioedema

Publications (1)

Publication Number Publication Date
GB201910125D0 true GB201910125D0 (en) 2019-08-28

Family

ID=67700187

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1910125.2A Ceased GB201910125D0 (en) 2019-06-14 2019-07-15 Treatments of angioedema

Country Status (18)

Country Link
US (1) US20220226293A1 (cg-RX-API-DMAC7.html)
EP (1) EP3982961A1 (cg-RX-API-DMAC7.html)
JP (1) JP7640474B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220024221A (cg-RX-API-DMAC7.html)
CN (2) CN113993520A (cg-RX-API-DMAC7.html)
AR (1) AR119159A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020293616A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021024447A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142220A1 (cg-RX-API-DMAC7.html)
CL (2) CL2021003243A1 (cg-RX-API-DMAC7.html)
GB (1) GB201910125D0 (cg-RX-API-DMAC7.html)
IL (1) IL288612A (cg-RX-API-DMAC7.html)
MA (1) MA56188A (cg-RX-API-DMAC7.html)
MX (1) MX2021014558A (cg-RX-API-DMAC7.html)
PH (1) PH12021552967A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202113375PA (cg-RX-API-DMAC7.html)
TW (1) TW202112371A (cg-RX-API-DMAC7.html)
WO (1) WO2020249979A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
US20250281397A1 (en) 2022-04-27 2025-09-11 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor
CN116003386B (zh) * 2022-11-20 2024-03-26 药康众拓(北京)医药科技有限公司 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
EP2051707B1 (en) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
ES2483802T3 (es) 2010-07-07 2014-08-07 The Medicines Company (Leipzig) Gmbh Inhibidores de serina proteasa
EP2595986A2 (en) 2010-07-14 2013-05-29 Addex Pharma SA Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
RU2712621C2 (ru) 2013-05-23 2020-01-30 Калвиста Фармасьютикалз Лимитед Азотсодержащие гетероциклические производные, полезные в качестве ингибитора калликреина плазмы
EP2886107A1 (en) * 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201609607D0 (en) * 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor
PL3716952T3 (pl) * 2017-11-29 2022-05-02 Kalvista Pharmaceuticals Limited Postacie dawkowania zawierające inhibitor kalikreiny osoczowej

Also Published As

Publication number Publication date
JP7640474B2 (ja) 2025-03-05
CA3142220A1 (en) 2020-12-17
SG11202113375PA (en) 2021-12-30
MA56188A (fr) 2022-04-20
CL2023000699A1 (es) 2023-10-30
AR119159A1 (es) 2021-12-01
JP2022537913A (ja) 2022-08-31
CN113993520A (zh) 2022-01-28
US20220226293A1 (en) 2022-07-21
BR112021024447A2 (pt) 2022-01-18
PH12021552967A1 (en) 2022-07-25
AU2020293616A1 (en) 2022-01-27
MX2021014558A (es) 2022-04-06
CN118078821A (zh) 2024-05-28
TW202112371A (zh) 2021-04-01
EP3982961A1 (en) 2022-04-20
IL288612A (en) 2022-02-01
WO2020249979A1 (en) 2020-12-17
CL2021003243A1 (es) 2022-09-30
KR20220024221A (ko) 2022-03-03

Similar Documents

Publication Publication Date Title
IL288615A (en) Treatments for hereditary angioedema
IL288612A (en) Treatments for angioedema
GB201804514D0 (en) Treatment of pyroptosis
IL290756A (en) Treatment of azoles
IL290983A (en) Treatment methods
RS67777B1 (sr) Postupak tretiranja tumora
GB201804515D0 (en) Treatment of necroptosis
IL287250A (en) treatment method
GB201907305D0 (en) Treatment of conditions
IL288526A (en) Thiarabine- and thiarabine prodrug-based treatments
GB201918853D0 (en) Methods of treatment
GB201914296D0 (en) Treatment
GB201912365D0 (en) Treatment
GB201906975D0 (en) Treatment of ards
EP3758702A4 (en) TREATMENT OF HEREDITARY ANGIOEDEMA
IL276421A (en) Testosterone therapy methods
PL3955933T3 (pl) Leczenie migreny
HK40070597A (en) Treatments of angioedema
GB201902579D0 (en) Treatment
GB201917908D0 (en) Novel treatments
GB201913636D0 (en) Novel treatments
GB201900942D0 (en) Methods of treatment
GB201917253D0 (en) Treatment of conditions
GB201904714D0 (en) Novel treatments
HK40075476A (en) Methods of treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)